Available online on 15.09.2024 at ijmspr.com

 International Journal of Medical Sciences and Pharma Research 

Open Access to Medical Science and Pharma Research

Copyright   © 2024 The  Author(s): This is an open-access article distributed under the terms of the CC BY-NC 4.0 which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited

Open Access                                                                                                                                                                                                                                             Review Article

 

Improving Cognitive Function: Blood Transfusions and Neurological Benefits in HIV Management

*Emmanuel Ifeanyi Obeagu 

Department of Medical Laboratory Science, Kampala International University, Uganda

 

 

Introduction

HIV remains a formidable global health challenge, affecting approximately 38 million people worldwide. While advancements in antiretroviral therapy (ART) have dramatically improved survival rates and the quality of life for those living with HIV, cognitive impairments remain a prevalent and persistent issue. These cognitive impairments, collectively known as HIV-associated neurocognitive disorders (HAND), encompass a spectrum ranging from asymptomatic neurocognitive impairment to HIV-associated dementia. Despite effective viral suppression achieved through ART, HAND continues to impact a significant proportion of the HIV-positive population, necessitating ongoing research into adjunctive therapies to mitigate these effects.^1-3 The central nervous system (CNS) is a critical target of HIV, with the virus entering the CNS early in the infection process. This invasion leads to chronic neuroinflammation and progressive neuronal damage, contributing significantly to the cognitive decline observed in HIV patients. ART, while effective in controlling systemic viral loads, often fails to completely eradicate the virus from the CNS. This viral persistence, coupled with ongoing neuroinflammatory processes, underscores the need for additional therapeutic strategies to protect and enhance cognitive function in this population.^4-5 Anemia is a common comorbidity in HIV-infected individuals, particularly those with advanced disease or on specific ART regimens. The presence of anemia can exacerbate cognitive dysfunction by reducing the oxygen-carrying capacity of the blood, thereby impairing cerebral oxygenation and neuronal function. Anemia-related cognitive impairments further compound the challenges faced by HIV patients, highlighting the importance of effective anemia management in this context.^6-7

Blood transfusions, a primary treatment modality for severe anemia, have emerged as a potential intervention to improve cognitive function in HIV patients. By increasing the oxygen-carrying capacity of the blood, transfusions can enhance cerebral oxygenation and potentially reverse anemia-related cognitive deficits. This review aims to explore the role of blood transfusions in improving cognitive function and providing neurological benefits in the management of HIV, considering both the direct effects on anemia and potential indirect neuroprotective effects.⁸ Several mechanisms may underlie the cognitive benefits of blood transfusions in HIV patients. First, by correcting anemia, transfusions can improve oxygen delivery to the brain, thereby supporting neuronal function and plasticity. Improved oxygenation can enhance cognitive domains such as attention, memory, and executive function, which are often impaired in HIV-associated neurocognitive disorders. Additionally, the correction of anemia can lead to overall improvements in physical health and energy levels, which may indirectly support cognitive function.^9-10 Beyond the direct effects on oxygen delivery, blood transfusions may also exert neuroprotective effects through modulation of systemic inflammation. Chronic inflammation is a hallmark of HIV infection and a key driver of neurocognitive decline. Elevated levels of pro-inflammatory cytokines contribute to neuroinflammation and neuronal damage. Blood transfusions have the potential to alter the inflammatory milieu, reducing the levels of these cytokines and thereby mitigating inflammation-induced neuronal damage. This anti-inflammatory effect could play a crucial role in preserving cognitive function in HIV patients.^11-12 Clinical studies have begun to shed light on the potential cognitive benefits of blood transfusions in HIV patients. Observational studies and clinical trials have indicated that HIV-positive individuals receiving blood transfusions for anemia management exhibit improvements in cognitive test scores, particularly in domains such as attention and executive function. These findings suggest that blood transfusions could be a valuable adjunctive therapy in the management of HIV-associated neurocognitive disorders.^13-14

However, the use of blood transfusions in HIV management is not without challenges. Risks associated with transfusions, such as transfusion reactions, infections, and iron overload, must be carefully weighed against the potential cognitive benefits. Moreover, the response to blood transfusions can vary significantly among individuals, influenced by factors such as the severity of anemia, co-infections, and the stage of HIV infection. Personalized approaches to transfusion therapy are essential to optimize outcomes and minimize risks.^15-16 Integrating blood transfusions with existing ART regimens presents another layer of complexity. ART remains the cornerstone of HIV management, and blood transfusions should be viewed as an adjunctive therapy rather than a replacement. Effective viral suppression through ART is crucial for controlling HIV replication and preventing further cognitive decline. Blood transfusions should complement these efforts by addressing specific complications like anemia and potentially modulating neuroinflammation.^17-18

HIV and Cognitive Dysfunction

HIV-associated neurocognitive disorders (HAND) encompass a spectrum of cognitive impairments that continue to affect a significant portion of the HIV-positive population, even in the era of effective antiretroviral therapy (ART). HAND includes a range of conditions from asymptomatic neurocognitive impairment (ANI) to mild neurocognitive disorder (MND) and, in severe cases, HIV-associated dementia (HAD). These conditions can significantly impair the quality of life, affecting daily functioning and adherence to HIV treatment.^19-20 The pathogenesis of HAND is complex and multifactorial. One of the primary mechanisms is the direct invasion of HIV into the central nervous system (CNS). HIV can cross the blood-brain barrier early in the course of infection, establishing a reservoir within the CNS. Once inside the brain, the virus can infect various cell types, including microglia and astrocytes, leading to the release of viral proteins and neurotoxic mediators that contribute to neuronal damage and dysfunction.²¹ Neuroinflammation plays a crucial role in the development of HAND. HIV infection triggers a chronic inflammatory response within the CNS, characterized by the activation of resident immune cells such as microglia and astrocytes, as well as the infiltration of peripheral immune cells. This inflammatory milieu results in the release of pro-inflammatory cytokines and chemokines, which can cause direct neuronal injury and disrupt synaptic function. Persistent neuroinflammation is a key driver of the neurocognitive decline observed in HAND.^22-23

The impact of HIV on the CNS is further compounded by systemic factors. Anemia, a common comorbidity in HIV-infected individuals, has been linked to cognitive impairment. The reduced oxygen-carrying capacity of the blood in anemia can impair cerebral oxygenation, leading to neuronal dysfunction and cognitive deficits. Additionally, co-infections, substance abuse, and other comorbid conditions prevalent among HIV-positive individuals can exacerbate cognitive dysfunction.^24-25 ART has been instrumental in reducing the incidence and severity of HAND by controlling systemic viral replication. However, ART does not fully eliminate HIV from the CNS, where the virus can persist in latent reservoirs. Moreover, some antiretroviral drugs have limited penetration across the blood-brain barrier, resulting in suboptimal viral suppression within the brain. This incomplete viral control allows ongoing neuroinflammation and neuronal damage, contributing to the persistence of HAND.^26-27 The clinical presentation of HAND can vary widely among individuals. Symptoms may include memory deficits, impaired attention and concentration, executive dysfunction, and motor abnormalities. These cognitive impairments can affect the ability to perform daily activities, maintain employment, and adhere to HIV treatment regimens. The heterogeneity in clinical presentation underscores the need for comprehensive neurocognitive assessments and personalized management strategies.^28-29 Diagnostic criteria for HAND have evolved over time, with current guidelines emphasizing the importance of neuropsychological testing to detect subtle cognitive deficits. Early identification of HAND is critical for implementing interventions that may slow the progression of cognitive decline. Neuroimaging techniques, such as magnetic resonance imaging (MRI) and positron emission tomography (PET), have also been employed to assess brain structure and function in HIV-positive individuals, providing valuable insights into the pathophysiology of HAND.³⁰

The Role of Blood Transfusions

Blood transfusions have long been a critical intervention for managing severe anemia, a common complication in HIV-infected individuals. While primarily used to restore the oxygen-carrying capacity of the blood, emerging evidence suggests that blood transfusions may also have beneficial effects on cognitive function and neurological health in HIV patients. Anemia, characterized by a deficiency in the number or quality of red blood cells, is prevalent among HIV-positive individuals, particularly those with advanced disease or on certain ART regimens. The reduced oxygen-carrying capacity of anemic blood can lead to cerebral hypoxia, impairing neuronal function and plasticity. Cognitive deficits associated with anemia include impairments in attention, memory, and executive function, which are critical for daily living and adherence to HIV treatment.³¹ Blood transfusions can directly address anemia by increasing the hemoglobin concentration and improving oxygen delivery to tissues, including the brain. This enhanced oxygenation can alleviate cerebral hypoxia, potentially reversing anemia-related cognitive impairments. Clinical studies have demonstrated that correcting anemia through blood transfusions can lead to significant improvements in cognitive performance in HIV-positive individuals. For example, patients have shown better results in tests measuring attention, memory, and executive function following transfusion therapy.³² Beyond the correction of anemia, blood transfusions may exert neuroprotective effects through modulation of systemic inflammation. Chronic inflammation is a hallmark of HIV infection and a key driver of neurocognitive decline. Elevated levels of pro-inflammatory cytokines and chemokines in HIV-infected individuals contribute to neuroinflammation, neuronal damage, and cognitive impairment. Blood transfusions can potentially alter this inflammatory milieu, reducing the levels of pro-inflammatory mediators and thereby mitigating inflammation-induced neuronal damage.³³ Studies have shown that blood transfusions can decrease systemic inflammation markers in HIV patients. This reduction in inflammation may translate to a decrease in neuroinflammation, thereby protecting the brain from further injury. The neuroprotective effects of blood transfusions could play a crucial role in preserving cognitive function in HIV patients, particularly those with elevated inflammatory markers.^34-35

The potential of blood transfusions to modulate neuroinflammation is particularly relevant in the context of HIV-associated neurocognitive disorders (HAND). Chronic neuroinflammation, driven by both direct viral effects and systemic inflammatory responses, contributes significantly to the pathogenesis of HAND. By reducing systemic and potentially neuroinflammation, blood transfusions could help to preserve neuronal integrity and function.³⁶ Research on neuroinflammation markers has indicated that blood transfusions can lead to reductions in pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α). These cytokines are known to play a role in neuroinflammatory processes and neuronal damage. By decreasing their levels, blood transfusions may help to protect against the cognitive decline associated with HAND. Clinical evidence supporting the cognitive benefits of blood transfusions in HIV patients is growing. Several studies have investigated the impact of blood transfusions on cognitive function, with promising results. For instance, a clinical trial involving HIV-positive individuals with anemia demonstrated that blood transfusions significantly improved cognitive test scores, particularly in domains such as attention and executive function. Observational studies have also noted that HIV patients receiving regular blood transfusions for anemia management exhibited slower cognitive decline compared to those not receiving transfusions.³⁷ While these findings are encouraging, it is important to note that the use of blood transfusions in HIV management must be approached with caution. The risks associated with transfusions, including transfusion reactions, infections, and iron overload, need to be carefully balanced against the potential cognitive benefits. Personalized approaches to transfusion therapy, considering individual patient characteristics and comorbid conditions, are essential to optimize outcomes and minimize risks. Integrating blood transfusions with existing ART regimens presents both opportunities and challenges. ART remains the cornerstone of HIV management, and blood transfusions should be considered an adjunctive therapy rather than a replacement. Effective viral suppression through ART is crucial for controlling HIV replication and preventing further cognitive decline. Blood transfusions should complement these efforts by addressing specific complications like anemia and potentially modulating neuroinflammation.³⁸ In clinical practice, the timing and frequency of blood transfusions need to be carefully planned to maximize their benefits while minimizing risks. Coordination between hematologists, neurologists, and infectious disease specialists is vital to develop individualized treatment plans that incorporate blood transfusions as part of a comprehensive HIV management strategy.

Challenges and Considerations

While blood transfusions offer promising benefits for improving cognitive function in HIV patients, their use is not without significant challenges and considerations. Ensuring the safe and effective integration of blood transfusions into HIV management requires careful attention to various factors, including potential risks, individual variability in response, and the need for comprehensive treatment strategies.

Risks and Complications

Blood transfusions, though life-saving in many contexts, carry inherent risks. One of the primary concerns is the risk of transfusion reactions, which can range from mild allergic reactions to severe, potentially life-threatening complications such as hemolytic reactions or transfusion-related acute lung injury (TRALI). These risks necessitate meticulous screening and monitoring of both blood donors and recipients. In addition to transfusion reactions, the risk of infections transmitted through blood transfusions, although significantly reduced by rigorous screening protocols, remains a concern. Pathogens such as bacteria, viruses, and parasites can be transmitted through contaminated blood products. This risk is particularly pertinent for HIV patients, who may already be immunocompromised and more susceptible to infections. Iron overload is another potential complication of repeated blood transfusions. Excess iron from transfused red blood cells can accumulate in organs such as the liver, heart, and endocrine glands, leading to organ dysfunction. Managing iron overload requires additional interventions, such as chelation therapy, which can add to the complexity and cost of treatment.³⁹

Individual Variability

The response to blood transfusions can vary significantly among HIV patients, influenced by factors such as the severity of anemia, the presence of co-infections, and the stage of HIV infection. Some patients may experience substantial cognitive improvements following transfusions, while others may show minimal or no benefit. Understanding the factors that contribute to this variability is crucial for optimizing treatment outcomes. Personalized approaches to transfusion therapy are essential. This involves tailoring the timing, frequency, and volume of transfusions to the specific needs of each patient. Close monitoring of hematologic parameters and cognitive function is necessary to assess the efficacy of transfusions and adjust treatment protocols accordingly.⁴⁰

Integration with Antiretroviral Therapy (ART)

Integrating blood transfusions with ART presents both opportunities and challenges. ART remains the cornerstone of HIV management, and maintaining effective viral suppression is critical for preventing further cognitive decline. Blood transfusions should be considered as an adjunctive therapy, complementing ART by addressing complications such as anemia and potentially reducing neuroinflammation. The timing of blood transfusions in relation to ART administration is an important consideration. Coordination between hematologists, neurologists, and infectious disease specialists is vital to ensure that transfusions do not interfere with the efficacy of ART or exacerbate potential side effects. Regular communication among the healthcare team is necessary to develop individualized treatment plans that optimize both antiviral and cognitive outcomes.⁴¹

Cost and Resource Allocation

Blood transfusions are resource-intensive procedures that require careful consideration of cost and availability, particularly in resource-limited settings where the burden of HIV is often highest. The cost of transfusion-related supplies, screening, and monitoring, as well as the potential need for additional treatments such as chelation therapy for iron overload, can strain healthcare resources. In resource-limited settings, prioritizing the use of blood transfusions for patients who are most likely to benefit is crucial. This may involve developing criteria for transfusion eligibility based on factors such as the severity of anemia and cognitive impairment, as well as the availability of alternative interventions. Ensuring equitable access to blood transfusions while managing limited resources is a significant challenge that requires strategic planning and policy development.⁴²

 

Long-Term Outcomes and Follow-Up

While short-term cognitive improvements following blood transfusions are promising, the long-term outcomes and sustainability of these benefits are not yet fully understood. Longitudinal studies are needed to assess the durability of cognitive improvements and the potential risks of long-term transfusion therapy. Regular follow-up and monitoring of patients who receive blood transfusions are essential to identify and address any emerging complications promptly.⁴²

Ethical and Psychological Considerations

The decision to undergo blood transfusions can have ethical and psychological implications for HIV patients. Some individuals may have concerns about the safety and risks of transfusions, particularly in light of historical issues related to blood safety. Addressing these concerns through informed consent processes, patient education, and counseling is essential to support patient autonomy and alleviate anxiety. Patients' psychological well-being must also be considered, as cognitive impairments and the prospect of transfusion therapy can impact mental health. Providing comprehensive support services, including mental health counseling and social support, is important for addressing the holistic needs of HIV patients undergoing blood transfusions.⁴³

Conclusion

Blood transfusions represent a promising but complex intervention for improving cognitive function and providing neurological benefits in the management of HIV. This review highlights the multifaceted role of blood transfusions in addressing anemia-related cognitive deficits, modulating systemic and neuroinflammation, and potentially preserving cognitive function in HIV-positive individuals. Despite these potential benefits, the use of blood transfusions in HIV care is not without significant challenges and risks.

The correction of anemia through blood transfusions can enhance cerebral oxygenation, thereby supporting neuronal function and cognitive performance. Additionally, the anti-inflammatory effects of transfusions may help mitigate neuroinflammation, a key driver of HIV-associated neurocognitive disorders (HAND). Clinical evidence suggests that blood transfusions can improve cognitive test scores, particularly in domains such as attention and executive function, highlighting their potential as an adjunctive therapy in HIV management.

References

1. Obeagu EI, Obeagu, GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. Elite Journal of Scientific Research and Review, 2024; 2(1): 37-50

2. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. Elite Journal of Laboratory Medicine, 2024; 2(1): 33-45

3. Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. Elite Journal of Medicine, 2024; 2(1):10-22

4. Obeagu EI, Obeagu GU, Ukibe NR, Oyebadejo SA. Anemia, iron, and HIV: decoding the interconnected pathways: A review. Medicine. 2024;103(2): e36937. https://doi.org/10.1097/MD.0000000000036937 PMid:38215133 PMCid:PMC10783375

5. Volberding P. The impact of anemia on quality of life in human immunodeficiency virus-infected patients. The Journal of infectious diseases. 2002;185(Supplement_2): S110-114. https://doi.org/10.1086/340198 PMid:12001031

6. Montoro M, Cucala M, Lanas Á, Villanueva C, Hervás AJ, Alcedo J, Gisbert JP, Aisa ÁP, Bujanda L, Calvet X, Mearin F. Indications and hemoglobin thresholds for red blood cell transfusion and iron replacement in adults with gastrointestinal bleeding: An algorithm proposed by gastroenterologists and patient blood management experts. Frontiers in Medicine. 2022; 9:903739. https://doi.org/10.3389/fmed.2022.903739 PMid:36186804 PMCid:PMC9519983

7. Obeagu EI, Obeagu GU. Eosinophil Dynamics in Pregnancy among Women Living with HIV: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024;10(1):11-24. https://doi.org/10.22270/ijmspr.v10i2.95

8. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. Asian Journal of Dental and Health Sciences. 2023;3(2):7-14. https://doi.org/10.22270/ajdhs.v3i2.39

9. Busch MP, Bloch EM, Kleinman S. Prevention of transfusion-transmitted infections. Blood, The Journal of the American Society of Hematology. 2019;133(17):1854-1864. https://doi.org/10.1182/blood-2018-11-833996 PMid:30808637

10. Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children Under 5 with Coexisting HIV and Severe Malaria: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):9-19.

11. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Neutrophil Dynamics: Unveiling Their Role in HIV Progression within Malaria Patients. Journal home page: http://www. journalijiar. com.;12(01).

12. Heron SE, Elahi S. HIV infection and compromised mucosal immunity: oral manifestations and systemic inflammation. Frontiers in immunology. 2017; 8:241. https://doi.org/10.3389/fimmu.2017.00241 PMid:28326084 PMCid:PMC5339276

13. Obeagu EI, Obeagu, GU. P-Selectin and Platelet Activation in HIV: Implications for Antiviral Therapy. Elite Journal of Scientific Research and Review, 2024; 2(1): 17-41

14. Obeagu EI, Obeagu GU. The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):30-40.

15. Obeagu EI, Anyiam AF, Obeagu GU. Erythropoietin Therapy in HIV-Infected Individuals: A Critical Review. Elite Journal of HIV, 2024; 2(1): 51-64

16. Obeagu EI, Obeagu GU. Strength in Unity: Building Support Networks for HIV Patients in Uganda. Elite Journal of Medicine, 2024; 2(1): 1-16

17. Bloch EM, Vermeulen M, Murphy E. Blood transfusion safety in Africa: a literature review of infectious disease and organizational challenges. Transfusion medicine reviews. 2012;26(2):164-180. https://doi.org/10.1016/j.tmrv.2011.07.006 PMid:21872426 PMCid:PMC3668661

18. Obeagu EI, Obeagu GU. Eosinophilic Changes in Placental Tissues of HIV-Positive Pregnant Women: A Review. Elite Journal of Laboratory Medicine, 2024; 2(1): 14-32

19. Obeagu EI, Obeagu, GU. The Crucial Role of Erythropoietin in Managing Anemia in HIV: A Review. Elite Journal of Scientific Research and Review, 2024; 2(1): 24-36

20. Cunningham-Rundles S, McNeeley DF, Moon A. Mechanisms of nutrient modulation of the immune response. Journal of Allergy and Clinical immunology. 2005;115(6):1119-1128. https://doi.org/10.1016/j.jaci.2005.04.036 PMid:15940121

21. Obeagu EI, Ubosi NI, Obeagu GU, Obeagu AA. Nutritional Strategies for Enhancing Immune Resilience in HIV: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):41-51. https://doi.org/10.22270/ijmspr.v10i2.102

22. Obeagu EI, Obeagu GU. Assessing Platelet Functionality in HIV Patients Receiving Antiretroviral Therapy: Implications for Risk Assessment. Elite Journal of HIV, 2024; 2(3): 14-26

23. Obeagu EI, Elamin EAI Obeagu GU. Understanding the Intersection of Highly Active Antiretroviral Therapy and Platelets in HIV Patients: A Review. Elite Journal of Haematology, 2024; 2(3): 111-117

24. Lotfi R, Kaltenmeier C, Lotze MT, Bergmann C. Until death do us part: necrosis and oxidation promote the tumor microenvironment. Transfusion Medicine and Hemotherapy. 2016 Mar 8;43(2):120-32. https://doi.org/10.1159/000444941 PMid:27226794 PMCid:PMC4872058

25. Cunha PP, Minogue E, Krause LC, Hess RM, Bargiela D, Wadsworth BJ, Barbieri L, Brombach C, Foskolou IP, Bogeski I, Velica P. Oxygen levels at the time of activation determine T cell persistence and immunotherapeutic efficacy. Elife. 2023;12: e84280. https://doi.org/10.7554/eLife.84280 PMid:37166103 PMCid:PMC10229120

26. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to Mothers with Severe Malaria, HIV, and Transfusion History: A Review. Elite Journal of Nursing and Health Science, 2024; 2(3): 38-58

27. Obeagu EI. Erythropoietin and the Immune System: Relevance in HIV Management. Elite Journal of Health Science, 2024; 2(3): 23-35

28. Zicari S, Sessa L, Cotugno N, Ruggiero A, Morrocchi E, Concato C, Rocca S, Zangari P, Manno EC, Palma P. Immune activation, inflammation, and non-AIDS co-morbidities in HIV-infected patients under long-term ART. Viruses. 2019;11(3):200. https://doi.org/10.3390/v11030200 PMid:30818749 PMCid:PMC6466530

29. Obeagu EI, Obeagu GU. Understanding Immune Cell Trafficking in Tuberculosis-HIV Coinfection: The Role of L-selectin Pathways. Elite Journal of Immunology, 2024; 2(2): 43-59

30. Obeagu EI, Obeagu GU. Anemia and Erythropoietin: Key Players in HIV Disease Progression. Elite Journal of Haematology, 2024; 2(3): 42-57

31. Balderson BH, Grothaus L, Harrison RG, McCoy K, Mahoney C, Catz S. Chronic illness burden and quality of life in an aging HIV population. AIDS care. 2013;25(4):451-458. https://doi.org/10.1080/09540121.2012.712669 PMid:22894702 PMCid:PMC3535557

32. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. Elite Journal of Nursing and Health Science, 2024; 2(2): 5-15

33. Obeagu EI, Obeagu GU. Immune Modulation in HIV-Positive Neonates: Insights and Implications for Clinical Management. Elite Journal of Nursing and Health Science, 2024; 2(3): 59-72

34. Chakraborty R, Cannella L, Cottone F, Efficace F. Quality of patient-reported outcome reporting in randomised controlled trials of haematological malignancies according to international quality standards: a systematic review. The Lancet Haematology. 2020;7(12):e892-901. https://doi.org/10.1016/S2352-3026(20)30292-1 PMid:33242446

35. Hébert PC, Fergusson D, Blajchman MA, Wells GA, Kmetic A, Coyle D, Heddle N, Germain M, Goldman M, Toye B, Schweitzer I. Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. Jama. 2003;289(15):1941-1949. https://doi.org/10.1001/jama.289.15.1941 PMid:12697796

36. Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood, The Journal of the American Society of Hematology. 2009;113(15):3406-3417. https://doi.org/10.1182/blood-2008-10-167643 PMid:19188662

37. Kaur P, Basu S. Transfusion-transmitted infections: existing and emerging pathogens. Journal of postgraduate medicine. 2005;51(2):146-151.

38. Wiersum-Osselton JC, Whitaker B, Grey S, Land K, Perez G, Rajbhandary S, Andrzejewski C, Bolton-Maggs P, Lucero H, Renaudier P, Robillard P. Revised international surveillance case definition of transfusion-associated circulatory overload: a classification agreement validation study. The Lancet Haematology. 2019;6(7):e350-358. https://doi.org/10.1016/S2352-3026(19)30080-8 PMid:31080132

39. Smit-Sibinga C, Pitman JP. Transmission of HIV through blood-how to bridge the knowledge gap. InHIV and AIDS-Updates on biology, immunology, epidemiology and treatment strategies 2011: 583-618. InTech, Rijeka, Croatia. https://doi.org/10.5772/19618 PMCid:PMC3157305

40. Slonim AD, Bish EK, Xie RS. Red blood cell transfusion safety: probabilistic risk assessment and cost/benefits of risk reduction strategies. Annals of Operations Research. 2014; 221:377-406. https://doi.org/10.1007/s10479-011-0925-0

41. Steffen KM, Spinella PC, Holdsworth LM, Ford MA, Lee GM, Asch SM, Proctor EK, Doctor A. Factors influencing implementation of blood transfusion recommendations in pediatric critical care units. Frontiers in Pediatrics. 2021; 9:800461. https://doi.org/10.3389/fped.2021.800461 PMid:34976903 PMCid:PMC8718763

42. Barro L, Drew VJ, Poda GG, Tagny CT, El‐Ekiaby M, Owusu‐Ofori S, Burnouf T. Blood transfusion in sub‐Saharan Africa: understanding the missing gap and responding to present and future challenges. Vox Sanguinis. 2018;113(8):726-736. https://doi.org/10.1111/vox.12705 PMid:30221365

43. Ako S, Njunda LA, Akum EA, Benjamin PT, Assob J. Hematological related disorders and transfusion of HIV patients on highly active antiretroviral therapy (HAART) in the South West Region of Cameroon: hematological monitory parameters for HIV follow-up. J HIV Retrovirus. 2018;4(1):5